We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

EKF Diagnostics Holdings plc (EKF) Ordinary 1p

Sell:35.00p Buy:35.60p 0 Change: 1.00p (2.94%)
FTSE AIM 100:1.22%
Market closed Prices as at close on 24 May 2022 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:35.00p
Buy:35.60p
Change: 1.00p (2.94%)
Market closed Prices as at close on 24 May 2022 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:35.00p
Buy:35.60p
Change: 1.00p (2.94%)
Market closed Prices as at close on 24 May 2022 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

EKF Diagnostics Holdings plc is primarily engaged in designing, developing, manufacturing and selling diagnostic instruments, reagents and ancillary products, as well as central laboratory reagents. The Company's point-of-care range includes hemoglobin analyzers, HbA1c analyzers and glucose analyzers for use in the screening, monitoring and diagnosis of patients, as well as rapid tests for pregnancy and common infectious diseases. Its Central Laboratory division includes a range of products for use in both large and small laboratory facilities. Its subsidiary, EKF Life Sciences, provides bulk diagnostic enzyme manufacturing and fermentation services. EKF Life Sciences specializes in producing enzymes, including Salicylate Hydroxylase and Beta-Hydroxybutyrate Dehydrogenase. Its products include Quo-Test A1c, Biosen, Quo-Lab A1c, UltraCrit, DiaSpect, HemataStat II and Creamatocrit Plus. It operates in Germany, the United States, Russia and the United Kingdom.

Contact details

Address:
Avon HSE, 19 Stanwell Road
PENARTH
CF64 2EZ
United Kingdom
Telephone:
+44 (029) 20710570
Website:
https://www.ekfdiagnostics.com/

Important dates

Future events
There are no future events available.
Past events
AGM 18 May 2022 18/05/22
Annual report 25 April 2022 25/04/22
Final results 29 March 2022 29/03/22
Trading Announcement 25 January 2022 25/01/22
Final dividend payment date 01 December 2021 01/12/21
Final ex-dividend date 04 November 2021 04/11/21
Interim results 14 September 2021 14/09/21
Trading Announcement 21 July 2021 21/07/21

General stock information

EPIC:
EKF
ISIN:
GB0031509804
Market cap:
£159.23 million
Shares in issue:
454.93 million
Sector:
Health Care Equipment & Services
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
FTSE AIM 100,FTSE AIM All Share

Key personnel

  • David Salter
    Chief Executive Officer, Executive Director
  • Julian Baines
    Non-Executive Deputy Chairman of the Board
  • Marc Davies
    Chief Financial Officer, Executive Director

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.